Recently, we developed TRAIL DR5 receptor-specific variant DR5-B, which has no affinity neither to DR4 nor to decoy receptors DcR1, DcR2, and osteoprotegerin and with enhanced pro-apoptotic activity in tumor cells [21]. Here, TNFRSF10B is linked to neoplasm.